Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

SELLAS also reported positive data from its Phase 2 trial of SLS009, a selective CDK9 inhibitor, with a median overall survival exceeding 7.7 months. Additionally, the company received FDA Rare ...

Interestingly, genetic analysis indicated that the patient who achieved complete response had MYC amplification and TP53 mutations, suggesting that CDK9 inhibition with SLS009 may overcome drug ...

Specifically, we anticipate full topline dataset from our Phase 2 trial of SLS009 in acute myeloid leukemia (AML) patients resistant to venetoclax combination therapies and FDA regulatory feedback ...

The trial, conducted and funded by GenFleet Therapeutics (Shanghai), Inc. (“Genfleet”), was an open-label single-arm multicenter Phase 2a study in China evaluating SLS009 in combination with ...

SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of“tambiciclib” as Recommended International Nonproprietary Name for ...